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Abstract
Summary Using in vivo microcomputed tomography (micro-
CT), we found in parathyroid hormone (PTH)-treated osteo-
penic rats linear increases in cortical and trabecular, due to
increased trabecular thickness and number, bone mass. Bone
was formed in cavities, leading to restoral of nearly cleaved
trabeculae. For the first time, effects in PTH-treated rats were
analyzed longitudinally.
Introduction Our aims were to over time (1) determine
changes in trabecular thickness and number after PTH, (2)
compare responses to PTH between the meta- and
epiphysis, (3) determine effects of PTH on mineralization
and mechanical properties, (4) determine locations of new
bone formation due to PTH on a microlevel, and (5)
determine the predictive value of bone structural properties
for gain in bone mass after PTH.
Methods Adult rats were divided into ovariectomy
(OVX; n=8), SHAM-OVX (n=8), and OVX and PTH
treatment (n=9). Between weeks 8 and 14, PTH rats
received daily subcutaneous PTH injections (60 μg/kg/day).
At weeks 0, 8, 10, 12, and 14, in vivo micro-CT scans were
made of the proximal and diaphyseal tibia. After sacrifice, all
tibiae were tested in three-point bending.
Results PTH increased bone volume fraction linearly over
time in meta- and epiphysis, accompanied by increased
trabecular thickness in both and increased trabecular
number only in the latter one. CT-estimated mineralization
increased in trabecular and remained constant in cortical
bone. Ultimate load and energy were increased and ultimate
displacement and stiffness unaltered compared to SHAM
rats. For those trabeculae analyzed, bone was formed
initially on places where it was most beneficial for
increasing their strength and later on to all surfaces.
Keywords Bonemicrostructure.Invivomicro-CT.
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Introduction
Daily injections of parathyroid hormone (PTH) have
anabolic effects on bone and are Food and Drug
Administration approved for treatment of vertebral frac-
tures associated with postmenopausal osteoporosis. The
effects of PTH have been extensively studied in the
ovariectomized rat. This is an animal model that has been
shown to be a good first predictor of treatment potential
of a drug for osteoporosis and as such is commonly used.
PTH markedly increases trabecular bone mass in the
proximal tibia, femoral neck, and lumbar vertebra of
ovariectomized, aged, and young rats [1–15]. Additionally,
it increases cortical width, cortical bone area, and axial
moments of inertia as a result of mostly endocortical bone
formation, leading to reduced bone marrow cavities and, to
a lesser extent, increased periosteal bone formation [7, 16–18].
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femoral neck, and femoral diaphysis increases accordingly in
rats after PTH treatment [2–4, 9]. Although the effects of
PTH have been extensively studied, some aspects are still
unclear and need further research.
Although most increases in trabecular bone mass after
PTH treatment have been reported to result from increased
trabecular thickness, in a few studies in dogs, rodents, and
monkeys, an increase in trabecular number was reported
after PTH treatment [19–25], which is an uncommon
feature in itself. The suggested mechanism for this was
the observation of longitudinal tunneling of thickened
trabeculae seen in histological sections as a remodeling
mechanism to maintain trabecular thickness within limits.
Tunneling of thickened individual trabeculae would convert
them into multiple trabeculae, resulting in a normalization
of trabecular thickness and an increase in trabecular
number. It has been suggested that trabecular thickness
will increase until it reaches a maximum, after which
intratrabecular resorption will take place [23]. This suggests
that changes in trabecular number and thickness may
depend on the structure at the start of the treatment and
may vary over time depending on dose and duration of
treatment and anatomical site. It is known that the same
increase in bone mass due to trabecular thickness or number
has different mechanical implications, with the latter one
having a higher increase in mechanical performance [26,
27]. Therefore, it is important to evaluate the changes in
both trabecular thickness and number after PTH treatment
over time to provide more insight into the potential of
increasing mechanical performance.
In most studies on PTH in rats, the metaphyseal
trabecular bone, often in the tibia, has been analyzed. It is
known, however, that even in adult rats, the growth plate
still shows some activity, though to a lesser extent than in
young animals, which inherently influences metaphyseal
trabecular bone [28]. As PTH is a naturally occurring
hormone that has an essential role in the growth plate, it can
be questioned whether the metaphysis would be the best
predictor of the effects of PTH in postmenopausal women,
in whom the growth plate has been closed since adoles-
cence. The neighboring epiphysis, which does not undergo
linear bone growth, may offer a more suitable translational
site for analyzing PTH effects. Also, loading patterns have
shown to be different between the meta- and epiphysis [29],
with higher strains occurring in the latter one. Moreover,
the response to PTH has shown to be directed toward
higher strain areas in a finite element modeling study in
osteoporotic patients [30] and has shown to be smaller in
the caudal vertebrae, where loads are relatively low,
compared to the lumbar vertebrae [31], indicating that
PTH effects may be mechanically directed. Taken together,
it would be highly relevant to compare the response to PTH
between the meta- and epiphysis, which has not previously
been done.
Conflicting results have been reported regarding the
influence of PTH on the degree and heterogeneity of bone
mineralization. In a study in patients, some aspects of
mineralization were altered after PTH use in men and
women [32]. In a study in rats, long-term treatment of rats
with PTH resulted in a slightly wider variation in
mineralization in the bone reflecting the newly formed
bone [18]. In two other rat studies, however, no influence of
PTH on mineralization was found [2, 33]. As altered
mineralization due to PTH may have detrimental effects on
mechanical behavior, in spite of a potentially increased
bone mass, it is important to further evaluate the effects of
PTH on mineralization and mechanical properties.
Most reported studies on effects of PTH in rats were
cross-sectional in design and rats were mostly sacrificed
after just one or two different treatment periods providing
little information about how exactly microstructure and
mineralization evolved over the course of treatment.
Additionally, as changes in bone mass and structure could
not be monitored in the same animal, no specific
knowledge was obtained about how and where new bone
is formed on a microlevel. Finally, it could not be
determined within a subject how much bone mass had
increased after PTH, which is clinically very important as
the patient’s response to PTH should be monitored and
ideally be predicted. Recently, however, in vivo micro-
computed tomography (micro-CT) scanners have become
available to monitor bone microstructure in small living
animals. With this tool, combined with image registration
software, we were able to analyze changes in bone
structure and mineralization over time after PTH treatment
in ovariectomized rats and hereby address the following
aims: (1) determine changes in trabecular thickness and
number after PTH over time, (2) compare responses to
PTH between the meta- and epiphysis, (3) determine
effects of PTH on mineralization and mechanical proper-
ties, (4) determine locations of new bone formation due to
PTH on a microlevel over time, and (5) determine the
predictive value of bone structural properties for gain in
bone mass after PTH.
Materials and methods
Animals
Twenty-five female 6-month-old virgin Wistar rats (Harlan
Laboratories, Horst, The Netherlands) were allowed to
acclimatize for 7 days before the start of the experiment.
The rats were maintained with a cycle of 12 h light and
12 h darkness and allowed to eat and drink ad libitum. The
1824 Osteoporos Int (2009) 20:1823–1835experiment was approved by the Animals Ethics Committee
of the University of Maastricht, The Netherlands. The rats
were divided into three groups (with equal weight distribu-
tions): control (n=8), ovariectomy (OVX; n=8), and OVX
and PTH treatment (n=9). All rats were ovariectomized at
week 0 and the control group underwent a SHAM
ovariectomy. Success of OVX was confirmed at necropsy
by determining atrophy of the uterine horns. Rats were left
untreated for 8 weeks to allow for osteopenia to develop.
After 8 weeks, rats in the PTH group received daily
subcutaneous injections of PTH (60 μg/kg/day) for 6 weeks.
This relatively high dose was chosen to maximize the
possibility of trabecular tunneling to occur and lies within
the dose range investigated in a dose-dependency study
[18]. Synthetic human PTH (1–34; Bachem, Bubendorf,
Switzerland) was dissolved in a vehicle of acidified saline
(0.1 N) and 2% rat serum. Body weight was measured
weekly, and the PTH dose adjusted accordingly. Rats were
sacrificed at 14 weeks by cervical dislocation under deep
anesthesia after the final CT scan.
Micro-CT scanning
Directly after the operation, a 6-mm micro CT-scan (70 kV,
114 μA, 1,000 projections per 180°, 261 ms integration
time) with an isotropic resolution of 15 μm was made of
the proximal tibia using an in vivo micro-CT scanner
(vivaCT 40, Scanco Medical AG, Brütissellen, Switzerland).
The CT scanner was calibrated and a beam-hardening
correction algorithm was applied to all scans [34]. Another
3.15-mm micro-CT scan of the diaphysis was made with an
isotropic resolution of 30 μm (70 kV, 114 μA, 250
projections per 180°, 350 ms integration time). Before this
measurement, the most distal and proximal point of the
tibia was located in a scout view to ensure that the exact
middle of the diaphysis was scanned. Follow-up in vivo CT
scans were made after 8, 10, 12, and 14 weeks to monitor
bone structure. Every follow-up scan was registered with
the first scan by using image registration software that
registers two scans based on minimizing the correlation
coefficient [35]. Total scanning time was 42 min, during
which the animal was anesthetized with isoflurane and the
scanned leg was placed in a custom-made leg-fixating
device. The design of the rat holder was such that the left
leg was not exposed to radiation while scanning the right
leg. Radiation damage to the scanned bone was not
expected to occur, based on a previous study, in which
8 weekly CT scans with the same radiation dose caused no
detected bone damage [36]. In that study, we also showed
that the reproducibility of all structural parameters was
high, with a coefficient of variation of about 1%.
From the CT scans, the metaphyseal trabecular bone,
epiphyseal trabecular bone, metaphyseal cortical bone, and
diaphyseal cortical bone were analyzed. For each analysis,
the estimated mineral density of the bone tissue was
determined based on the linear correlation between CT
attenuation coefficient and bone mineral density (BMD).
Image processing of all scans included Gaussian filtering
and segmentation as described elsewhere in detail [36]. In
brief, the same filtering and segmentation values were used
for every measurement of each animal (trabecular bone:
sigma=0.7, support=1, threshold density=0.575 g HA/cc,
equivalent to 24% of maximal grayscale value; cortical
bone: sigma=0.8, support=1, threshold density=0.642 g
HA/cc, equivalent to 26% of maximal grayscale value).
From every baseline and follow-up CT scan, the trabecular
bone of the meta- and epiphyseal areas were manually
selected and bone structural parameters (bone volume
fraction (BV/TV), connectivity density (Conn.D), structure
model index (SMI), trabecular number, thickness, and
separation (Tb.N, Tb.Th, Tb.Sp)) were automatically
determined (Fig. 1). Cortical bone of the metaphysis was
manually selected from the hundred most distal slices.
From the CT scan of the diaphysis, all slices were manually
selected. Cortical thickness and polar moment of inertia
(pMOI) were determined. The selected cortical bone in the
meta- and diaphysis at weeks 8 and 14 was registered for all
PTH-treated rats to determine to what extent bone forma-
tion over 6 weeks was due to endosteal or periosteal
apposition.
Trabecular tunneling
We expected trabecular tunneling only to occur, if at all, in
the thickest trabeculae; hence, for all PTH-treated rats, the
meta- and epiphyseal trabecular bones of the CT scans of
Fig. 1 CT scan of a proximal metaphysis showing hand-drawn contours of the metaphyseal and epiphyseal trabecular bone, b proximal
metaphysis showing hand-drawn contours of metaphyseal cortical bone, and c diaphyseal cortical bone
Osteoporos Int (2009) 20:1823–1835 1825weeks 12 and 14 were registered. After registration, the two
CT scans were overlaid and visually checked for trabecular
tunneling. This was done by going through the registered
images per five slices, first from proximal to distal end and
then from anterior to posterior sides while specifically
looking for trabeculae that were thick at week 12 to see
whether they were split in two at week 14, by using
histologic sections from the literature as image to look for.
To determine whether there is a maximum trabecular
thickness, after which trabecular tunneling takes place, we
analyzed the distribution of trabecular thickness in the
epiphysis of all rats at all time points. The scanner software
provides outputs of counts per bin and trabecular thickness
was categorized in bins of 15 μm.
Prediction of gain in bone mass after PTH treatment
We hypothesizedthatseveralstructuralpropertiesmaypredict
the gain in bone mass after PTH, such as bone surface at the
start of PTH treatment, bone mass at the start of PTH
treatment, bone mass before ovariectomy, and amount of
bone mass loss after ovariectomy. Therefore, a linear
correlation was determined between several structural param-
eters and the gain in bone mass, gain in bone volume fraction,
final bone mass, and final bone volume fraction after PTH
treatment. This was done for the PTH-treated rats only.
Three-point bending of tibiae
After sacrifice, all tibiae were dissected and frozen in
phosphate buffered saline solution at −20°C. They were
thawed prior to three-point bending. The tibia was placed on
the lateral surface on two rounded supporting bars with a
distance of 2.4 cm. A preload of 1 N was applied (ZWICK,
Z020) at the medial surface of the diaphysis by lowering a
third rounded bar. A constant displacement rate of 6 mm/min
was applied until failure. Displacement was measured from
the actuator displacement transducer of the testing machine.
From the force–displacement curve, the following mechan-
ical parameters were determined: (1) ultimate load, defined
as the maximum load, (2) displacement at ultimate load,
which was corrected for the toe region, (3) extrinsic stiffness,
calculated as the slope in the linear region between 40% and
80% of the ultimate load, and (4) energy to ultimate load,
defined as the area under the curve until ultimate load.
Statistics
A one-way analysis of variance (ANOVA) with repeated
measures was performed to compare the PTH-treated and
OVX groups during treatment between weeks 8 and 14. A
one-way ANOVA with a Bonferroni post hoc test was used
to determine differences between the groups at certain time
points, for all parameters. Furthermore, a one-way ANOVA
with repeated measures was performed to compare the
OVX and SHAM groups between weeks 0 and 8. Finally,
an ANOVA with repeated measures was performed in the
SHAM group to determine effects of aging. All p values
below 0.05 were considered significant.
Results
Metaphyseal structural parameters
At week 8, the ovariectomized groups displayed loss of
BV/TV, Conn.D, Tb.N, and Tb.Th and an increase in SMI
and Tb.Sp, indicating the development of osteopenia
(Fig. 2). Beyond 8 weeks, the untreated OVX group
showed further deterioration of bone structure except for
Tb.Th, which increased.
Daily injections with PTH reversed the effects of OVX
and prevented further deterioration of bone structure.
PTH-treated animals displayed a crude plate-like trabecu-
lar bone structure and bone marrow cavity was reduced
compared to OVX rats. Over the course of weeks 8 to 14,
a significant effect of time, effect of PTH treatment, and
an interaction of PTH treatment and time were found for
all structural parameters. PTH directly led to an increase in
BV/TV accompanied by an increase in Tb.Th and
prevention of further loss of Tb.N and further increase of
Tb.Sp. This increase in BV/TV and Tb.Th was linear and
continued until sacrifice. Loss of Conn.D was prevented
and SMI decreased by PTH treatment. In the time frame of
weeks 8 to 10, an interaction of PTH treatment and time
was found, indicating that the effects of PTH were present
within 2 weeks. After 2 weeks of PTH treatment, all
structural parameters were already significantly different
from the OVX group. After 6 weeks of PTH treatment,
BV/TV and SMI were not significantly different between
the PTH and SHAM groups. Tb.N and Conn.D were
significantly lower and Tb.Th and Tb.Sp were significant-
ly higher in the PTH than in the SHAM group. In the
SHAM group, BV/TV, Conn.D, and Tb.N were signifi-
cantly decreased and Tb.Sp significantly increased over
time as a result of aging.
Epiphyseal structural parameters
At week 8, the ovariectomized groups displayed loss of
BV/TV, Conn.D, and Tb.N and an increase in SMI and Tb.
Sp, indicating the development of osteopenia (Fig. 3).
Changes in the epiphysis, however, were much smaller than
in the metaphysis. Beyond 8 weeks, the untreated OVX
group showed further deterioration of bone structure except
for Tb.Th, which gradually increased over time.
1826 Osteoporos Int (2009) 20:1823–1835Over the course of weeks 8 to 14, a significant interaction
of PTH treatment and time was found for all structural
parameters except for Conn.D. PTH treatment led to a direct
increase in bone volume fraction, accompanied by increases
in Tb.N and Tb.Th, while Tb.Sp decreased. This increase in
BV/TV and Tb.N was linear and continued until sacrifice,
while the increase in Tb.Th waned over time. SMI decreased
after PTH treatment, while loss of Conn.D was not
prevented. In the time frame of weeks 8 to 10, a significant
interaction of PTH treatment and time was found for all
structural parameters except for Conn.D, indicating that the
effectsofPTH werepresentwithin2weeks. After 2weeksof
PTH treatment, BV/TV and SMI were already significantly
different from the OVX group and not significantly different
from the SHAM group while Tb.Th was significantly higher
in the PTH group than the OVX and SHAM groups. After
Fig. 3 Structural parameters in the epiphyseal, proximal tibia for all groups at all time points (mean ± standard deviation)
Fig. 2 Structural parameters in the metaphyseal proximal tibia for all groups at all time points (mean ± standard deviation)
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significantly higher than the SHAM group and than baseline
values. SMI, Tb.N, and Tb.Sp were the same as the SHAM
group, while Conn.D remained reduced. In the SHAM
group, Conn.D significantly decreased and Tb.Th signifi-
cantly increased over time as a result of aging.
Cortical thickness and polar moment of inertia
in the metaphysis and diaphysis
Cortical thickness and the polar moment of inertia in the
metaphysis did not significantly change within the 8 weeks
after OVX compared to the SHAM group (Fig. 4). PTH
treatment led to a sharp linear increase in cortical thickness
and pMOI, which were both significantly different from the
OVX group over time. Visual inspection of registered
images of weeks 8 and 14 showed that bone formation was
slightly more due to endosteal than periosteal apposition
and that bone formation did not take place on all parts of
the surface in the same degree (Fig. 5).
Cortical thickness in the diaphysis increased after OVX
almost reaching significance (p=0.07). PTH treatment led
to an even sharper increase, which was linear over time and
significantly different from the untreated group. The pMOI
increased significantly after OVX in the first 8 weeks. After
8 weeks, this increase waned in the OVX group, while it
increased significantly more in the PTH-treated group.
Visual inspection of registered images of weeks 8 and 14
showed that bone formation was slightly more due to
periosteal than endosteal apposition and that bone forma-
tion had taken place quite evenly over the whole surface.
Cortical thickness and pMOI significantly and gradually
increased over time in the metaphysis and the diaphysis of
the SHAM group as a result of aging.
Mineralization of meta- and epiphyseal trabecular bone
tissue and meta- and diaphyseal cortical bone tissue
At the start of the experiment, CT-estimated bone mineral
densityinthemetaphysealtrabecular andcorticalbonetissue
was significantlyhigher intheSHAMgroupthanintheother
groups. However, because of the use of follow-up data and
repeated measures design, we were still able to determine
significant effectsof OVX and PTH on bone mineral density.
C o m p a r e dt oS H A M ,O V Xw a sf o u n dt ol e a dt oa
significantly lower increase in mineral density of meta- and
diaphyseal,corticalbonetissueoverthefirst 8weeks,butdid
not significantly affect trabecular bone tissue (Fig. 6). Over
weeks 8 to 14, the meta- and epiphyseal trabecular bone
tissue of the PTH group was found to have a significantly
Fig. 4 Cortical thickness and
polar moment of inertia (pMOI)
in the meta- and diaphysis of
the tibia for all groups at all
time points (mean ± standard
deviation)
1828 Osteoporos Int (2009) 20:1823–1835more increasing bone mineral density than that of the OVX
group. Cortical bone mineral density was not affected by
PTH treatment. Bone mineral density of all measured bone
areas was found to significantly increase over time in the
SHAM group.
Trabecular tunneling and remodeling
For all PTH-treated rats, no cases of trabecular tunneling
were detected in metaphyseal trabecular bone between
weeks 12 and 14. For several rats, one trabecula was
selected and analyzed as it developed over time after PTH
treatment. Figure 7 shows how PTH in this particular
trabecula first led to filling and overfilling of cavities, while
later, more bone was added to the surface of the trabecula
resulting in a thicker trabecula. Also, resorption still
appeared to take place in this trabecula. Another trabecula
after segmentation of the image appeared cleaved due to
OVX-induced increased resorption. PTH treatment led to
bone formation, which took place where it was most
beneficial, i.e., at the cleaved site, restoring the trabecula.
This indicates that there probably was still a thin line of
bone left in the center, which was unaccounted for after
segmentation, but large enough for bone formation to take
place. It was found that for all rats, the maximum trabecular
thickness continued to increase over time. Therefore, no
maximum limit for trabecular thickness appeared to be
present.
Prediction of gain in bone mass after PTH treatment
The linear correlations between several structural parame-
ters and the gains in bone mass, gain in bone volume
fraction, final bone mass, and final bone volume fraction
after PTH treatment varied between the specific parameters
as well as bone regions (Table 1). More significant
Fig. 6 CT-estimated bone
mineral density of metaphyseal
trabecular bone, metaphyseal
cortical bone, diaphyseal cortical
bone, and epiphyseal trabecular
bone (mean ± standard deviation)
Fig. 5 Registered images of metaphyseal (left) and diaphyseal (right)
cortical bone taken at weeks 8 and 14 showing bone formation during
6 weeks in the cortex of a PTH-treated rat. Gray is bone at week 8,
black is newly formed bone
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epiphysis. Best correlations were found between BV and
B V / T Va tw e e k0a n dB Va n dB V / T Va tw e e k1 4 ,
respectively, in both the meta- and epiphysis. Paradoxically,
the loss of bone after OVX did not predict the gain of bone
after PTH treatment well. From structural parameters
evaluated at week 8, bone surface (BS) was the best
predictor of the gain in bone after PTH. While BVand BV/
TVat week 8 predicted the gain in bone mass over the next
6 weeks quite well, the predictive value of BV and BV/TV
at weeks 8, 10, and 12 for the following 2 weeks was poor
to nonsignificant. Interestingly, in the epiphysis, the slopes
of these relations were negative, indicating that the higher
BV and BV/TV, the lower the gain. All other significant
relations had a positive slope.
Three-point bending of tibiae
Ultimate load and energy in the PTH group were
significantly higher than in the SHAM group (Fig. 8).
Table 1 Linear correlation between several structural parameters to predict gain in bone mass, gain in bone volume fraction, final bone mass, or
final bone volume fraction
Predictive variable Outcome variable Metaphysis Epiphysis
r
2 Slope r
2 Slope
BS at weeks 8, 10, and 12 ΔBV/TV over weeks 8–10, 10–12, and 12–14 0.42 0.0003 0.23 0.0011
BS at weeks 8, 10, and 12 ΔBV over weeks 8–10, 10–12, and 12–14 0.40 0.0077 n.s. –
BV/TV at weeks 8, 10, and 12 ΔBV/TV over weeks 8–10, 10–12, and 12–14 n.s. – 0.41 −0.23
BV at weeks 8, 10, and 12 ΔBV over weeks 8–10, 10–12, and 12–14 0.21 0.13 0.25 −0.21
ΔBV/TV over weeks 0–8 ΔBV/TV over weeks 8–14 n.s. – n.s. –
ΔBV over weeks 0–8 ΔBV over weeks 8–14 0.48 0.95 n.s. –
BS at week 8 ΔBV/TV over weeks 8–14 0.86 0.0012 n.s. –
BS at week 8 ΔBV over weeks 8–14 0.77 0.030 n.s –
BV/TV at week 8 ΔBV/TV over weeks 8–14 0.66 0.76 n.s. –
BV at week 8 ΔBV over weeks 8–14 0.69 0.88 n.s. –
BV/TV at week 0 BV/TV at week 14 0.81 1.3 0.85 1.6
BV at week 0 BV at week 14 0.89 1.3 0.93 0.96
Fig. 7 A trabecula in two PTH-treated ovariectomized rats was tracked
over time to determine the development of bone formation (1 and 2). On
the left of 1 and 2, you see three-dimensional segmented images of a
trabecula, after PTH treatment is started at week 8, taken at weeks 8 (a),
10 (b), 12 (c), and 14 (d). On the right, you see overlaid two-
dimensional segmented sections comparing weeks 8 and 10 (e), 10 and
12 (f), and 12 and 14 (g). Yellow indicates resorbed bone, green newly
formed bone, and red unchanged bone. Bone formation is clearly seen
over time in both trabeculae. In trabecula 1, bone is mostly deposited in
the cavities in the first 2 weeks, while later on bone is added to the
surface. In trabecula 2, the trabecula appears cleaved after segmentation,
although most likely there was still a thin line of bone present. PTH
treatment leads to bone formation at the cleaved site, where it is most
needed hereby restoring the trabecula
1830 Osteoporos Int (2009) 20:1823–1835Ultimate load and energy in the OVX group tended to be
slightly higher and lower than the SHAM and PTH group,
respectively, though this did not reach significance. No
significant differences were found in extrinsic stiffness and
ultimate displacement between all groups, although the
trend between groups in extrinsic stiffness was similar to
the trend in ultimate load.
Discussion
For the first time, the effects of PTH treatment on trabecular
and cortical bone were analyzed longitudinally with an in
vivo micro-CT scanner in the same ovariectomized rats for
6 weeks. It was found that (1) PTH treatment led to
constant linear increases in trabecular bone mass of the
meta- and epiphysis due to linearly increasing trabecular
thickness in both regions and linearly increasing trabecular
number in the epiphysis, (2) a different response to PTH
was seen between the meta- and epiphysis in terms of
structural parameters, (3) PTH resulted in increased
trabecular tissue mineralization and unaltered cortical tissue
mineralization as well as slightly improved bending
properties, (4) for those trabeculae analyzed, bone was
formed initially on places where it was most beneficial for
increasing their strength and later on to all surfaces, and (5)
bone mass after PTH treatment for each rat individually
was best predicted by bone mass at the start of the
experiment.
In the metaphyseal trabecular bone, PTH treatment led to
a constant linear increase in bone volume fraction during
6 weeks accompanied by a constantly increasing trabecular
thickness and an inhibition of further loss of trabecular
number. Although this is the first in vivo report on bone
structural parameters, our results agree with previous cross-
sectional studies on the eventual effects of PTH on
trabecular metaphyseal bone [8, 10–15, 22] and with an in
vivo report on changes in bone mineral density [37]. In the
epiphyseal trabecular bone, PTH treatment also led to an
increasing bone volume fraction, accompanied by a linearly
increasing trabecular number while trabecular thickness
alsoincreased,whichwanedovertime.Previously,preventive
treatment with PTH (at time point of OVX) in ovariec-
tomized rats led to an increased bone volume fraction,
trabecular number, and thickness in the tibial epiphysis,
compared to untreated OVX and SHAM rats in a cross-
sectional study [38], though exact values were not reported.
This concurs, however, with the increases that we found
after recovering treatment (after osteopenia) with PTH in
the epiphysis. For the first time now, bone microstructure in
the epiphysis over time was reported after PTH use. The
increase in bone volume fraction after PTH treatment over
6 weeks in the meta- and epiphysis was almost exactly the
same. This increase resulted in the epiphysis in values that
were above SHAM level while in the metaphysis values
were still below SHAM. This similar increase suggests that
the anabolic response to PTH is comparable in both
locations.
Interestingly, the response to PTH treatment was
slightly different between the meta- and epiphyseal
trabecular bone, with the most striking difference being
an increasing trabecular number in the epiphysis, while it
stayed constant in the metaphysis. There are several
possible explanations for this difference between the
meta- and epiphysis and for the increase in trabecular
number in the epiphysis. The deterioration of bone mass
and structure after ovariectomy in the epiphysis was much
smaller than in the metaphysis. Therefore, at the start of
PTH treatment, the state of the bone was quite different
between the meta- and epiphysis, with the latter one
having a higher trabecular thickness and structure model
index. It has been suggested that after PTH treatment,
trabeculae will initially become thicker until a certain
maximum thickness is reached [23]. Trabecular tunneling
would then take place, after which thick trabeculae are
cleaved into two smaller ones, which has been shown to
occur in different species [19, 20, 23–25]. This implies
that trabeculae will never grow beyond a certain maximum
thickness, the value of which may depend on species and
anatomical site. As trabecular thickness was higher in the
epi- than the metaphysis, this could be an explanation for
the increase in trabecular number in the epiphysis and the
absence of this in the metaphysis. To test this, we analyzed
the distribution of trabecular thickness in the epiphysis of
Fig. 8 Ultimate load, ultimate
displacement, extrinsic stiffness,
and energy determined from
three-point bending test on tibiae
after sacrifice at 14 weeks.
*p<0.05 compared to SHAM
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maximum trabecular thickness continued to increase until
week 14. This therefore does not support the idea of a
maximum intrinsic trabecular thickness. This is further
supported by the fact that trabecular thickness in the
metaphysis at the final time point was higher than in the
epiphysis, while trabecular number did not increase. Also,
no cases of tunneling were seen in the epiphysis after
visual inspection. Another explanation could lie in the
decrease of total volume of interest over time in the
epiphysis seen in the CT scans due to endosteal apposi-
tion. In theory, it could be that the number of trabeculae in
the area close to the cortex is lower than average. This
would suggest that merely a decrease in total volume
would lead to an increase in trabecular number. We
analyzed this possibility by using the hand-drawn contour
file from week 14 for the CT scan of week 8, which
excludes the outer trabecular region. We then analyzed
bone structural parameters again and found that trabecular
number was not increased compared to when using the
original contour file for week 8, and therefore, this
possibility is excluded. Another option is that the
relatively large amount of the plate-like bone enables
trabecular tunneling in a different fashion than previously
reported in rod-like bone by fenestration of plates, which
may be difficult to see in the CT scans. A final possibility
is that after 8 weeks, thin trabeculae were removed during
segmentation. When these trabeculae increased in thick-
ness, they were included resulting in an increased
trabecular number at 14 weeks. This phenomenon is
shown in Fig. 7.
Tissue mineral density of meta- and epiphyseal trabec-
ular bone significantly increased over time after PTH
treatment, while cortical bone in the meta- and diaphysis
was unaffected. It has previously been found that ash
density of the vertebral body, including cortical and
trabecular bone, was significantly increased in PTH-
treated ovariectomized rats compared to untreated ovariec-
tomized rats already after 5 weeks, while after 16 weeks of
PTH treatment, still no effects were found on the femoral,
diaphyseal, and cortical bone [2]. In another study, using
quantitative backscattered electron imaging to calculate the
degree and homogeneity of mineralization, however, no
significant effect of 5.5 months of PTH treatment was
found on the cortical and trabecular bone of PTH-treated
ovariectomized rats [33]. In yet another study on the long-
term effects of PTH on mineralization in rats, no significant
influences were found, although there was a slightly wider
variation in mineralization in the bone reflecting the newly
formed bone [18]. These differences in results in rats may
be due to different methods applied to determine mineral-
ization. Also, the different study durations are likely to play
a role, as new bone formed in response to PTH is probably
undermineralized; however, mineralization may increase
thereafter. It should be noted that CT-based measurements
of the degree of mineralization may be less reliable than
other methods such as back-scattered electron imaging and
microradiographic techniques. The unaffected cortical
mineral density is supported by the bending results. Our
bending data agree with three-point bending tests in the
femur where an increase in ultimate load and extrinsic
stiffness after PTH treatment was found in ovariectomized
rats [39, 40]. It can be seen that the trends between groups
in ultimate load, extrinsic stiffness, and calculated polar
moment of inertia are similar, which indicates that the polar
moment of inertia was a good predictor of ultimate load and
extrinsic stiffness. Ultimate displacement did not differ
between all groups, which suggests that the newly formed
bone was of similar quality as the old bone and indicates
that PTH treatment did not lead to more brittle or ductile
mechanical behavior. This is further supported by unaltered
tissue mineralization values in the diaphyseal tissue, i.e.,
cortical bone.
Individual trabeculae were tracked over time during PTH
treatment in all rats by using image registration software.
With this method, we were able to monitor bone formation
after PTH treatment on a microlevel and gather insight into
how and where PTH treatment leads to new bone. In many
trabeculae, it appeared that in the first 2 weeks, mostly
cavities were filled, while later on bone was added to the
outer surface. It has been suggested that increases in bone
mass after PTH occur by remodeling- and modeling-based
bone formation [41] and plasma markers in PTH-treated
patients have shown that modeling increases directly after
the onset of treatment [42]. Our data suggest that in rats,
initially remodeling-based bone formation takes place, as
cavities are filled with bone, while later, modeling-based
bone formation is more pronounced as bone is added to the
outer surface, which does not appear to have been resorbed
first. This will need to be further validated. For several
other trabeculae, it was seen that ovariectomy led to severe
disruption of the trabecula to the point of almost complete
cleavage after segmentation of the images. PTH treatment
led to bone deposition there where most beneficial,
resulting in full restoral of the trabecula. This could be
explained by Frost’s mechanostat, which states that bone is
deposited where strains and stresses are the highest. Since
in an almost cleaved trabecula merely a thin line of bone
was present at certain locations, strains and stresses would
be the highest at these locations leading to bone formation
there. This suggests that PTH-induced bone formation is, at
least in part, mechanically driven. This agrees with results
from two finite element studies on CT scans of osteoporotic
patients treated with teriparatide (rhPTH (1–34)), in which
it was found that bone was mostly deposited on locations of
high strains [30] and that teriparatide increased vertebral
1832 Osteoporos Int (2009) 20:1823–1835strength by altering the distribution of density within the
vertebra [43].
It is clinically relevant to be able to predict to what
extent a patient will respond to PTH in order to determine
the best treatment. In a clinical study, several characteristics
like BMD before treatment and age were examined for
correlations with the increase in BMD after PTH treatment;
however, no strong correlations were found [44]. In our
study, the best predictor of final bone mass and bone
volume fraction in both the meta- and epiphysis was bone
mass and bone volume fraction at the start of the
experiment, before ovariectomy. If these results would be
translational to clinical practice, which needs to be tested,
this would indicate that bone mineral density before
menopause would predict bone mineral density after PTH
treatment of osteoporotic patients.
Cortical bone mass increased linearly over time after
PTH treatment in the meta- and diaphysis while marrow
cavity volume decreased. In several cross-sectional studies,
in which the effect of between 8 weeks and 6 months of
PTH treatment was evaluated in ovariectomized rats, an
increase in cortical bone mass was found [6, 14, 38]. In a
study in ovariectomized mice, it was found that within
3 weeks of PTH treatment, cortical thickness was signifi-
cantly increased in the metaphysis and after 7 weeks,
cortical thickness was even higher [45]. Diaphyseal cortical
thickness was significantly increased only after 7 weeks of
treatment. In another study, the effects of PTH treatment on
metaphyseal cortical thickness of the tibia in ovariectomized
rats was studied over time by using peripheral quantitative
computed tomography (pQCT) [46]. A linear increase in
cortical thickness was found until about 6 weeks, after
which the effect reached a plateau. Taken together, our
linear increase in dia- and metaphyseal cortical bone after
PTH treatment agrees with the literature. In the metaphysis,
no effect of ovariectomy was found on cortical bone
parameters, which agrees with previous studies [47, 48].
Interestingly, cortical thickness and polar moment of inertia
in the diaphysis increased after ovariectomy, which is in
contrast to significant decreases [21, 49] and no significant
changes [50, 51] previously reported.
It has previously been found that PTH leads to a
predominance of endocortical over periosteal bone apposi-
tion in cortical bone [16–18, 52]. Based on registered
images of weeks 8 and 14, before and after PTH treatment,
we found that endosteal and periosteal bone apposition both
took place in the meta- and diaphysis, with a slight
predominance of endosteal formation in the former one
and a slight predominance of periosteal formation in the
latter one. This difference between the meta- and diaphysis
could be related to the following. It is seen after
ovariectomy that periosteal bone apposition increases and
bone marrow cavity increases due to endocortical resorption.
PTH treatment would add to this periosteal expansion
resulting in a relatively higher periosteal bone formation
rate compared to the metaphysis. It is also possible that
the increased endocortical metaphyseal bone is the result
of “corticalization” of the subcortical trabecular elements.
We also saw that while the degree of bone apposition was
evenly distributed over the endo- and periosteal surface of
the diaphysis, it varied quite largely over the endo- and
periosteal surface of the metaphysis. This could indicate
that bone apposition is stimulated more in certain
locations than others, which may also partly be the result
of remodeling due to linear growth, which still is present
in the adult rat [28, 53].
This study was limited by a treatment period with PTH
of 6 weeks. It was found that bone volume fraction in the
meta- and epiphyseal trabecular bone and cortical thickness
in the meta- and diaphysis continued to increase linearly. It
is very likely though that these increases will wane after a
longer treatment period. Although no trabecular tunneling
was detected, it would be interesting to determine how
trabecular structure would develop further over time as
bone mass continues to increase. Another limitation lies in
the translation of our rat study to clinical practice. It is
known that rat cortical bone is not subject to Haversian
remodeling [28], which has shown to lead to different
responses to PTH compared to species with Haversian
remodeling, in which negative [54, 55] and no effects [56,
57] on cortical thickness were found. Also, rats in our study
were subjected to serial radiation resulting from CT
scanning; however, we have previously shown that eight
weekly scans do not lead to detectable radiation damage
[36]. Since the total number of scans in this study was six
and the shortest interval between scans was 2 weeks, we do
not expect any radiation damage. Finally, concern has been
raised regarding the predictive value of CT-derived tissue
mineralization [58, 59]. It could be that thicker trabeculae
would lead to more beam hardening effects, which would
result in a lower average mineralization. The fact that we
found an increased mineralization degree indicates that this
is most likely not due to beam hardening. An explanation
for our results could be that when trabeculae thicken after
PTH treatment, the center is not being remodeled anymore
resulting in an increased mineralization of this bone. The
algorithm calculating the mineralization peels off two
voxels of the outside of the bone, which is probably the
new less mineralized bone. This is thus not incorporated in
the calculation, which could result in the increased
mineralization.
This study demonstrated that 6 weeks of PTH treatment
of osteopenic rats led to increases in bone volume fraction of
the tibial meta- and epiphysis as well as increases in cortical
bone mass of the tibial meta- and diaphysis. By using an in
vivo micro-CT method, it was shown that net bone
Osteoporos Int (2009) 20:1823–1835 1833formation started directly after the onset of treatment and
continued with the same rate for at least 6 weeks in both
trabecular and cortical bone. Deposition of bone appeared to
be mechanically driven, resulting in cleaved trabeculae being
fully restored again. The increase in bone volume fraction
was similar in the meta- and epiphysis; however, the
resulting changes in microstructure were different, which
may have different mechanical implications.
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